Block T, et al. - Researchers here reported a combined analysis of all controlled Phase 2/3 studies to describe antipsychotic differences between treatment with mifepristone or placebo. In addition, they evaluated the relative contributions to response of attaining an a priori–defined, high-mifepristone plasma level and markers of glucocorticoid receptor (GR) antagonism (increases in ACTH and cortisol) with treatment. In this study, the high-mifepristone-plasma-level group displayed the strongest association with response, followed by changes in ACTH and cortisol. With the 1200 mg/d dose, they most likely achieved therapeutic plasma levels of mifepristone.